|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer.
|
30807643 |
2019 |
|
Hormone refractory prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Follow-up analysis found that patients who progressed to castration-resistant prostate cancer (CRPC) have a lower frequency of ERG protein expression at initial biopsies compared to androgen deprivation therapy (ADT)-sensitive cases (14.1% vs 23.5%, P = 0.042), but Kaplan-Meier curve showed that ERG protein expression was not an independent prognostic marker.
|
30900303 |
2019 |
|
Hormone refractory prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Both ERRα and ERG exhibited a positive expression correlation in a castration-resistant prostate cancer (CRPC) xenograft model VCaP-CRPC.
|
30042415 |
2018 |
|
Hormone refractory prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The combined analyses of pro-NPY and ERG expression was not associated with risk of BF (p = 0.7), castration-based treatment (p = 0.8), CRPC (p = 0.4) or PCa-specific death (p = 0.5).
|
30191621 |
2018 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
An exploratory endpoint was the association of Triptocare baseline variables (including TMPRSS2-ERG and PCA3 scores) and PCA3 score at Triptocare last value available with CRPC onset.
|
26919403 |
2017 |
|
Hormone refractory prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Gene expression profile analysis shows some ERG-BRD4 co-target genes are upregulated in CRPC compared to hormone-naïve counterparts.
|
27223260 |
2016 |
|
Hormone refractory prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We hypothesize that TMPRSS2-ERG fusions regulate androgen biosynthetic enzyme (ABE) gene expression and the production of androgens, which contributes to the development of CRPC.
|
25754347 |
2015 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, recent data suggest that ERG IHC may be less sensitive for ERG rearrangements in castration-resistant prostate cancer (CRPC).
|
25043157 |
2014 |
|
Hormone refractory prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
As surrogate for CTCs we measured KLK3, PCA3, and TMPRSS2-ERG messenger RNA (mRNA) in the peripheral blood mononuclear cell (PBMC) fraction from a castration-resistant prostate cancer (CRPC) patient cohort and three control groups.
|
25043536 |
2014 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, analysis of a cohort of 34 men with metastatic CRPC treated with docetaxel chemotherapy reveals that ERG-overexpressing prostate cancers have twice the chance of docetaxel resistance than ERG-negative cancers.
|
25420520 |
2014 |
|
Hormone refractory prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer.
|
24469092 |
2014 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rearrangements other than the typical TMPRSS2-ERG fusion were confirmed by karyotype analysis and found in 7% of primary cancer and 13% of CRPC tumors.
|
23352841 |
2013 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Especially among TMPRSS2:ERG fusion-positive CRPC tumors, AR mRNA and ERG mRNA levels are strongly correlated (rho = 0.64, P<0.001).
|
24098661 |
2013 |
|
Hormone refractory prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ERG protein expression is restricted to neoplastic prostatic epithelium and is present at lower rates in metastatic and CRPC compared to localized PCa.
|
23746715 |
2013 |
|
Hormone refractory prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression level of the TMPRSS2-ERG gene was studied in various histological grades of prostate cancer and castration-resistant prostate cancer (CPRC).
|
23578236 |
2013 |
|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Proteins that physically interact with the AR, such as the ERG gene fusion product, FOXA1, MLL2, UTX (also known as KDM6A) and ASXL1 were found to be mutated in CRPC.
|
22722839 |
2012 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
To run a phase II clinical trial of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer (CRPC), based on evidence that cytarabine might be effective in men with abnormalities of ERG oncogenes.
|
22313860 |
2012 |
|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The ERG rearrangement occurred at a lower frequency in distant metastatic prostate cancer compared to local recurrent castration-resistant prostate cancer.
|
22767266 |
2012 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The TMPRSS2-ERG expressing DuCaP-N cell line represents human prostate cancer prior to endocrine treatment, and its parental DuCaP cell line is a model for CRPC.
|
20687225 |
2010 |
|
Hormone refractory prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, TFF3 overexpression enhances ERG-mediated cell invasion in CRPC prostate cancer cells.
|
21170267 |
2010 |
|
Hormone refractory prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We then used quantitative reverse transcription-PCR to show that ERG expression was maintained in CRPC.
|
19339269 |
2009 |
|
Hormone refractory prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer.
|
19584279 |
2009 |